Neuralink N2 — Expanded Clinical Programme

The Opportunity

Neuralink's N2 device programme expands the PRIME study to 50 paralysis patients across 12 sites globally, while advancing the R&D roadmap toward a second-generation implant with 10× electrode density and wireless charging. This raise supports clinical operations, device manufacturing scale-up, and regulatory pathway for FDA Breakthrough Device approval.

• First BCI to achieve sustained telepathic cursor control in humans
• FDA Breakthrough Device designation secured
• N2 device targets 10× electrode density vs N1
• 50-patient PRIME expansion across 12 global sites
• Licensing pipeline value estimated at $8B by independent analysts

Project Milestones